As of 2025-07-01, the Intrinsic Value of Aurinia Pharmaceuticals Inc (AUP.TO) is (83.32) CAD. This AUP.TO valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 16.76 CAD, the upside of Aurinia Pharmaceuticals Inc is -597.10%.
The range of the Intrinsic Value is (472.82) - (46.43) CAD
Based on its market price of 16.76 CAD and our intrinsic valuation, Aurinia Pharmaceuticals Inc (AUP.TO) is overvalued by 597.10%.
Note: result may not be accurate due to the invalid valuation result of DCF model.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (472.82) - (46.43) | (83.32) | -597.1% |
| DCF (Growth 10y) | (54.15) - (514.41) | (94.04) | -661.1% |
| Fair Value | -5.50 - -5.50 | -5.50 | -132.83% |
| EPV | (11.76) - (13.60) | (12.68) | -175.6% |
| DDM - Stable | (29.04) - (584.46) | (306.75) | -1930.3% |
| DDM - Multi | (29.98) - (467.64) | (56.26) | -435.7% |
| Market Cap (mil) | 2,147.89 |
| Beta | 0.35 |
| Outstanding shares (mil) | 128.16 |
| Enterprise Value (mil) | 1,932.82 |
| Market risk premium | 4.74% |
| Cost of Equity | 5.60% |
| Cost of Debt | 5.00% |
| WACC | 5.30% |